Mweempwa et al. reported that a 66-year-old patient with metastatic PCC harboring a RET-SEPTIN9 fusion gene demonstrated a rapid response to selpercatinib: a 46% reduction in the sum of diameters of the target lesions within 12 weeks of treatment [24]. Here, SEPTIN9 is linked to adrenal gland pheochromocytoma.